Thermo Fisher Scientific Inc (TMO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Thermo Fisher Scientific Inc stock (TMO) is currently trading at $490.77. Thermo Fisher Scientific Inc PE ratio is 27.62. Thermo Fisher Scientific Inc PS ratio (Price-to-Sales) is 4.09. Analyst consensus price target for TMO is $663.96. WallStSmart rates TMO as Hold.
Thermo Fisher Scientific Inc (TMO) stock price prediction for 2030: Base case $354.47. Bull case $443.09. Bear case $265.85. See full TMO 2030 price forecast and methodology on WallStSmart.
- TMO PE ratio analysis and historical PE chart
- TMO PS ratio (Price-to-Sales) history and trend
- TMO intrinsic value — DCF, Graham Number, EPV models
- TMO stock price prediction 2025 2026 2027 2028 2029 2030
- TMO fair value vs current price
- TMO insider transactions and insider buying
- Is TMO undervalued or overvalued?
- Thermo Fisher Scientific Inc financial analysis — revenue, earnings, cash flow
- TMO Piotroski F-Score and Altman Z-Score
- TMO analyst price target and Smart Rating
Thermo Fisher Scientific Inc
📊 No data available
Try selecting a different time range
TMO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Thermo Fisher Scientific Inc (TMO)
TMO trades 28% above its Graham fair value of $384.82, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Thermo Fisher Scientific Inc (TMO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, profit margin. Fundamentals are solid but monitor weak areas for improvement.
Thermo Fisher Scientific Inc (TMO) Key Strengths (4)
95.54% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $21 kept per $100 revenue
Strong profitability: $15 kept per $100 revenue
Supporting Valuation Data
Thermo Fisher Scientific Inc (TMO) Areas to Watch (6)
Premium valuation at 4.1x annual revenue
Premium pricing at 3.3x book value
Modest revenue growth at 7.20%
Modest earnings growth at 9.30%
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Supporting Valuation Data
Thermo Fisher Scientific Inc (TMO) Detailed Analysis Report
Overall Assessment
This company scores 59/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 4.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Operating Margin. Profitability is solid with Operating Margin at 21.20%, Profit Margin at 15.00%.
The Bear Case
The primary concerns are Price/Sales, Price/Book, Revenue Growth. Some valuation metrics including PEG Ratio (1.76), Price/Sales (4.09), Price/Book (3.30) suggest expensive pricing. Growth concerns include Revenue Growth at 7.20%, EPS Growth at 9.30%, which may limit upside. Profitability pressure is visible in Return on Equity at 13.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 13.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 7.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (Price/Sales, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TMO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TMO's Price-to-Sales ratio of 4.09x trades at a 44% premium to its historical average of 2.83x (91th percentile). The current valuation is 26% below its historical high of 5.56x set in Jan 2007, and 198% above its historical low of 1.37x in Dec 2008.
WallStSmart Analysis Synopsis
Data-driven financial summary for Thermo Fisher Scientific Inc (TMO) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Thermo Fisher Scientific Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 44.6B with 7% growth year-over-year. Profit margins of 15.0% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 3.0B in free cash flow and 3.5B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Debt management: total debt of 39.4B is significantly higher than cash (9.9B). Monitor refinancing risk.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Thermo Fisher Scientific Inc.
Bottom Line
Thermo Fisher Scientific Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Thermo Fisher Scientific Inc(TMO)
NYSE
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.